Morcellation Controversy; do we have an Answer?

Bharti Joshi*

Consultant Sant IVF Center, Jindal Nursing Home Sector 20 D Chandigarh, India

Submission: December 23, 2017; Published: March 19, 2018

*Corresponding author: Bharti Joshi, Consultant Sant IVF Center, Jindal Nursing Home Sector 20 D Chandigarh, -#529, 16 D, FF, Chandigarh, India, Email: drbharti09@gmail.com

Introduction

Minimal invasive surgeries are now well established in practice for many years and have gained widespread importance due to less postoperative morbidity and mortality. More innovative techniques has been developed over a period to enhance these procedures and optimize specimen retrieval. Morcellation, a technique used to facilitate removal of large specimen through fragmentation was introduced in 1973 and now has become an integral part in most of the gynecological surgeries. Two approaches i.e. manual and power morcellation have eased out the delivery of large specimen in laparoscopic surgery. Most of the hysterectomies and myomectomies are performed laparoscopically now a days with comparable outcome to other surgical approaches. There is no difference in terms of complications, risk of myoma recurrence or reproductive outcome apart from the conversion rate of 0.3% to 0.5% to open myomectomy [1-4]. No doubt, these new innovations have improved the capabilities of clinicians but are not without risks and legal litigations. There is a risk of tissue trauma, dispersion of morcellated tissue throughout abdominal cavity and a serious consequence of dissemination of occult malignancy in laparoscopic morcellation. Based on unforeseen cases, Food and Drug administration (FDA) released statement in 2014 against morcellation of uterine specimen because of oncological risk. Comprehensive review by FDA found the risk of morcellating an unsuspected uterine sarcoma to be 1 in 352 and uterine leiomyosarcoma 1 in 498. The women in peri- or postmenopausal group and those for en bloc specimen are not appropriate for power morcellation. After this, significant drop in the number of minimal invasive approaches was observed which led to the development of new techniques like contained morcellation and has pushed this topic to the forefront for the discussion. The recommendation against morcellation has been challenged by many service providers and has greatly influenced trends in gynaecological surgeries. The intent of the index article is to throw light on the current recommendations of laparoscopic myomectomy and morcellation.

Potential Risks of Morcellation

Leiomyosarcoma is highly aggressive tumour of rare occurrence. The incidence of occult leiomyosarcoma in benign gynaecological surgeries is reported to be very low [5-7]. Theoretical risk of cytological dissemination of occult malignancy in the peritoneal cavity after morcellation has been evaluated. A study by Von Bargen et al revealed 1.2% incidence of occult malignancy in benign gynaecological surgeries with no case of leiomyosarcoma [8]. Graebe et al. [9] observed 0.22% risk of sarcoma after uterine morcellation. The prevalence of uterine malignancy among 40,000 women undergoing myomectomy with or without contained morcellation was found to be 0.09% and 0.18% respectively [10]. Higher incidence of uterine malignancies reported by Perkins et al. [11] may be due to the inclusion of all premalignant and malignant uterine pathologies in his study.

Do we have Promising Solutions?

FDA ban on the use of power morcellation left negative impact on surgical outcomes and health costs, therefore confronted by these obstacles surgeons came out with novel approach of contained morcellation. Various studies has reported feasibility as well as success of this approach and no difference was observed in the perioperative outcome to that of uncontained system [12-14] Abdominopelvic washings before and after laparoscopic morcellation with containment showed no evidence of cytological dissemination [15]. Cohen et al detected dye leak in some trials but many authors reported no spillage or bag related failures in contained morcellation of upto 2Kgm specimen [16-20]. Authors have observed upto 26 minute increase in operative time in contained morcellation as compared to uncontained with similar outcome [11,12].

Contained vaginal morcellation although seems to be an alternative option but risk of bladder, bowel injuries and atrophic vagina in old age group limits its application. Potential risk of
cytological dissemination in this procedure further demand need of new resistant devices.

Laparotomy, minilaparotomy or vaginal hysterectomy definitely remain possible option to avoid tissue morcellation but at an increased cost and surgical complications.

Future Perspectives

There is no doubt that prognosis of leiomyosarcoma gets worsened by distant spread but data on the oncological risk of morcellation needs further validation. The largest data till date of morcellated leiomyosarcoma had shown significantly worse prognosis as compared to open surgery but interestingly out of these 41 patients only one had laparoscopic morcellation and majority of them underwent cold knife morcellation through minilaparotomy [23, 24]. Another important thing to be noted is that combined mortality from minimum invasive surgery with potential risk of malignancy would be less than the open hysterectomy.

There is no ideal way to predict the malignant potential of fibroid as none of imaging techniques or sociodemographic factors seem promising. Does it worth to abandon all minimal invasive surgeries at the given risk of occult malignancy. The take away from the literature is that any kind of tissue disruption at the time of surgery worsens the prognosis. The clinical implications of the same can be extrapolated to the non-invasive treatment like MRI guided, laser ablation or uterine artery embolization which leave disrupted tissue inside the body.

Take home message is that it would not be justified to counsel all patients of fibroids for open myomectomy and hysterectomy. There should be thorough discussion with patients regarding pros and cons of laparoscopic surgery and morcellation. Further research should focus on new innovative techniques of contained morcellation and alternatives of specimen retrieval.

References

1. Bhave Chittawar P, Franik S, Pouwer AW, Farquhar C, et al. (2014) Minimally invasive surgical techniques versus open myomectomy for uterine fibroids. Cochrane Database Syst Rev 10: Cd004638.
2. Gobern JM, Rosemeyer CJ, Barter JF, Steren AJ (2013) Comparison of robotic, laparoscopic, and abdominal myomectomy in a community hospital. JSLS 17(1): 116-20.
3. Shen Q, Chen M, Wang Y, Zhou Q, Tao X, et al. Effects of laparoscopic versus minilaparotomic myomectomy on uterine leiomyoma: a meta-analysis. J Minim Invasive Gynecol 22(2): 177-184.
4. Shin DG, Yoo HJ, Lee YA, Kwon IS, Lee KH (2017) Recurrence factors and reproductive outcomes of laparoscopic myomectomy and minilaparotomic myomectomy for uterine leiomyomas. Obstetrics Gynecol Sci 60(2): 193-199.
5. Tön R, Kilke GS, Phelps JY (2015) A medical-legal review of power morcellation in the face of the recent FDA warning and litigation. J Minim Invasive Gynecol 22(4): 564-572.
6. Damascia MR, Chan PK, Slonim M, Ang WC, Healey MG, et al. Incidence of malignancy and myoma variants at surgery for presumed benign symptomatic myomas. J Minim Invasive Gynecol 24(4): 659-664.
7. Rodríguez AM, Asoglu MR, Sak ME, Tan A, Borahay MA, et al. (2016) Incidence of occult leiomyosarcoma in presumed morcellation cases: a database study. Eur J Obstet Gynecol Reprod Biol 197: 31-35.
8. von Bungen EC, Grimes CL, Mishra K, Wang R, Haviland MJ, et al. (2017) Prevalence of occult pre-malignant or malignant pathology at the time of uterine morcellation for benign disease. Int J Gynaecol Obstet 137(2): 123-128.
9. Graebe K, Garcia-Soto A, Aziz M, Valarezo V, Heller PB, et al. (2015) Incidental power morcellation of malignancy: a retrospective cohort study. JAMA Oncol 136(2): 274-277.
10. Wright JD, Tergas AI, Cui R, Burke WM, Hou JY, et al. (2015) Use of electric power morcellation and prevalence of underlying cancer in women who undergo myomectomy. JAMA Oncol 1(1): 69-77.
11. Perkins RB, Handal-Orifice R, Bhanate AD, Lin M, Paasche-Orlow MK, et al. Risk of undetected cancer at the time of laparoscopic supracervical hysterectomy and laparoscopic myomectomy: implications for the use of power morcellation. Women’s Health Issues 26(1): 21-26.
12. Gherzi F, Casarin J, De Francesco G, Puggina P, Uccella S, et al. (2018) Transvaginal contained tissue extraction after laparoscopic myomectomy: a cohort study. BJOG 125(3): 367-373.
13. Leal MAI, Pihlén A, De Santiago J, Zapardiel I (2017) Novel technique for contained power morcellation through umbilicus with insufflated bag. Gynecol Obstet Invest 82(2): 205-207.
14. Steller C, Cholkeri-Singh A, Sasaki K, Miller CE (2017) Power morcellation using a contained bag system. JSLS 21(1).
15. Ikenna DE, Paintal A, Milad MP (2016) Feasibility of washings at the time of laparoscopic power morcellation: a pilot study. J Minim Invasive Gynecol 23(5): 793-797.
16. Cohen SL, Greenberg JA, Wang KC, Srouji SS, Gargiulo AR, et al. (2014) Risk of leakage and tissue dissemination with various contained tissue extraction (CTE) techniques: an in vitro pilot study. J Minim Invasive Gynecol 21(5): 935-939.
17. Cohen SL, Morris SN, Brown DN, Greenberg JA, Walsh BW, et al. (2016) Contained tissue extraction using power morcellation: prospective evaluation of leakage parameters. Am J Obstet Gynecol 214(2): 257.e1-257.
18. Paul PG, Thomas M, Davis T, et al. (2016) Contained morcellation for laparoscopic myomectomy within a specially designed bag. J Minim Invasive Gynecol 23(2): 257-260.
19. Aoki Y, Matsuura M, Matsuno T, Yamamoto T (2016) Single-site in-bag morcellation achieved via direct puncture of the pseudoperitoneum cap, a cordless electric morcellator, and a 5-mm flexible scope. Eur J Obstetr Gynecol Reprod Biol 201: 126-130.
20. Frascà C, Degli Esposti E, Arena A, Tuzzato G, Moro E, et al. (2018) Can in-bag manual morcellation represent an alternative to uncontained power morcellation in laparoscopic myomectomy? a randomized controlled trial. Gynecol Obstet Invest 83(1): 52-56.
21. Winner B, Porter A, Vellozo S, Biest S (2015) Uncontained compared with contained power morcellation in total laparoscopic hysterectomy. Obstet Gynecol 126(4): 834-838.
22. Vargas MV, Cohen SL, Fuchs-Weizman N, Wang KC, Manouchehi E, et al. (2015) Open power morcellation versus contained power morcellation within an insufflated isolation bag comparison of perioperative outcomes. J Minim Invasive Gynecol 22(3): 433-438.
23. Park JY, Park SK, Kim DY, Kim JH, Kim YM (2011) The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma. Gynecol Oncol 122(2): 255-259.
24. Perri T, Korach J, Sadetzki S, Oberman B, Fridman E, et al. (2009) Uterine leiomyosarcoma: does the primary surgical procedure matter? Int J Gynecol Cancer 19(2): 257-260.

This work is licensed under Creative Commons Attribution 4.0 License
DOI: 10.19080/JGWH.2018.09.555756

Your next submission with Juniper Publishers will reach you the below assets
- Quality Editorial service
- Swift Peer Review
- Reprints availability
- E-prints Service
- Manuscript Podcast for convenient understanding
- Global attainment for your research
- Manuscript accessibility in different formats (Pdf, E-pub, Full Text, Audio)
- Unceasing customer service

Track the below URL for one-step submission
https://juniperpublishers.com/online-submission.php

How to cite this article: Bharti Joshi. Morcellation Controversy; do we have an Answer?. J Gynecol Women's Health 2018; 9(1): 555756.
DOI: 10.19080/JGWH.2018.09.555756.